Blackstone Inc. is considering selling Alinamin Pharmaceutical Co., a Japanese consumer healthcare firm previously owned by Takeda Pharmaceutical Co., according to individuals familiar with the matter.
The world’s largest alternative asset manager, Blackstone, is working with financial advisers on the potential sale of Tokyo-based Alinamin, which could be valued at around ¥300 billion ($1.9 billion). Interested parties reportedly include CVC Capital Partners Plc, EQT AB, and
All the week’s industry events straight to your inbox.
By signing up you agree to our terms of use and privacy policy.
7 Bell Yard, London, England, WC2A 2JR
You will soon receive a Reset Password link
By signing up you agree to terms of use and privacy policy.
Continue with Facebook Continue with Google